Trials / Recruiting
RecruitingNCT06608342
Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblastic Leukemia
Clinical Study of Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment for Adult High-risk Acute Lymphoblastic Leukemia
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To observe the efficacy and side effects of autologous hematopoietic stem cell transplantation combined with CD19-CART for adult acute lymphoblastic leukemia, and to evaluate the safety and efficacy of this regimen in the treatment of acute lymphoblastic leukemia.
Detailed description
To observe the efficacy and side effects of autologous hematopoietic stem cell transplantation combined with CD19-CART for adult acute lymphoblastic leukemia, and to evaluate the safety and efficacy of this regimen in the treatment of acute lymphoblastic leukemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Autologous hematopoietic stem cell transplantation combined with CD19-CART | Autologous CD19-CAR T cells were transfused +7 days after autologous hematopoietic stem cell transplantation |
Timeline
- Start date
- 2024-06-25
- Primary completion
- 2026-05-30
- Completion
- 2028-05-30
- First posted
- 2024-09-23
- Last updated
- 2024-09-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06608342. Inclusion in this directory is not an endorsement.